| Similar Articles |
|---|
 |
Pharmaceutical Executive
September 1, 2006 |
Finance: Good Alternatives With more ways to raise cash, biotechs with hot products can extend their independence.   |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
The Motley Fool
August 2, 2004
Charly Travers |
What's a Drug Worth? The value of small biotech companies is in their investigational drug programs. |
The Motley Fool
August 19, 2010
Brian Orelli |
High Risk, High Reward. At Least It Was Cheap! Biogen licenses a drug to treat ALS. |
Pharmaceutical Executive
May 1, 2009 |
The Shakeout When it comes to licensing in this market, there are winners and losers. Learn the new rules of the game. |
Pharmaceutical Executive
February 1, 2009
Flamenbaum et al. |
Stream Power Convert future revenue into present value with alternative approaches to access capital. |
Pharmaceutical Executive
June 1, 2012 |
2012 Dealmakers Outlook With Yankee Stadium as the backdrop, Pharm Exec convened on its annual panel of heavy hitters in business development to crack the bat on best practices in licensing and for the year ahead. |
The Motley Fool
January 10, 2007
Brian Lawler |
Seattle Genetics' Big Deal The small biopharmaceutical firm signed a lucrative collaboration deal with biopharma powerhouse Genentech and shares were up 24% as a result. |
Investment Advisor
December 2005
Greg B. Scott |
Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns. |
The Motley Fool
December 21, 2010
Brian Orelli |
4 Drugmakers, 5 Deals, Christmas Is Here It looks like there were a lot of people in the business development offices at pharmaceutical companies looking to get their work done before taking off for the holidays. Check out all the deals that were announced yesterday. |
Entrepreneur
June 2004
Marc Diener |
Fair Share? Whether it's a commission, a participation, a royalty or equity, here are 10 ways to know if you're getting an equal slice of the pie. |
Pharmaceutical Executive
May 1, 2005 |
Thought Leaders: Playing Field in Biotech/Pharma Partnerships Levels As infrastructure and business savvy within biotechs become increasingly sophisticated, the sector's relationship with pharma is taking on a new shape. An interview with industry veteran Lisa Drakeman on how to integrate cultures and processes and where pharma is falling short. |
The Motley Fool
July 27, 2010
Jim Mueller |
3 Stocks to Play Biotech Here are three promising ideas for this exciting area. |
Commercial Investment Real Estate
May/Jun 2007
Robert L. Ward |
NPV Review For commercial real estate users and investors, understanding these net present value functions aids the real estate decision-making process. |
Pharmaceutical Executive
March 1, 2007 |
Finance: Q&A with Annette Grimaldi It's now more lucrative for a small pharmaceutical company to sell than to go public. Here is how the past year has shaped up - and what might be next on the horizon. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
Pharmaceutical Executive
September 1, 2006
Nick Rogerson |
Slow Deal Flow? 10 Quick Fixes for Getting Business Development Back on Track |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
Pharmaceutical Executive
October 1, 2006
Clinton & Koroneos |
Learn & Confirm At Wyeth, a sweeping set of initiatives is transforming the R&D operation - and spotlighting a possible future for drug development. |
Commercial Investment Real Estate
May/Jun 2007
Donald J. Valachi |
Excel at Financial Analysis Calculations For commercial real estate professionals, spreadsheet software can help you calculate discounted cash flow measures of value and return. |
The Motley Fool
July 27, 2007
Tom Taulli |
A New Phase for Phase Forward Phase Forward wins a multi-million dollar contract for its clinical trial software; this infusion of cash provides even more resources for pursuing more growth. |
Chemistry World
September 2007
Derek Lowe |
Column: In the Pipeline Will Phase Zero trials actually help drug development? |
The Motley Fool
December 16, 2011
Brian Orelli |
Biotech Royalties, Almost as Good as Cash They're flexible, and all royalties have value. |
The Motley Fool
January 26, 2006
Bill Mann |
Lehman Shows Little Elan At $17, maybe the stock was a little ahead of itself. But a $5 target? Last week, a Lehman Brothers analyst triggered a bit of a selling panic when he said that Elan Pharmaceuticals was overvalued -- by about 70%. |
The Motley Fool
May 1, 2007
Brian Lawler |
Cardiome Plays Dealmaker Cardiome signs a deal to develop one of Eli Lilly's drug candidates. Investors, take note. |
The Motley Fool
July 22, 2005
Tim Beyers |
Ben Graham at the Poker Table Great poker players actually have a lot in common with great value investors. ESPN began airing The World Series of Poker this week. If you closely watch the high-stakes action, you'll receive a lesson in value investing. |
Bank Technology News
February 2011
John Adams |
Analyze Payments, Get More Money Payments have always been a pipeline to the wallet, but Sandy Spring Bank plans to wield the latest data management tools and analysis to use "paying" as a window to the customer's financial services soul. |
U.S. Banker
October 2006
Lee Conrad |
New Industry Index Aims to Quantify The Progress of Corporate Payments Companies still make most of their payments with paper checks, but new VICOR-commissioned research suggests a major change is afoot. Restless bankers are more than ready. |
Investment Advisor
June 2009
Mike Patton |
Temperament & Tools To do the job right, the fiduciary financial planner needs the right temperament, and the right tools. Here's how one advisor does it. |
Commercial Investment Real Estate
Jan/Feb 2013
Craig Haskell |
Value Play Value investors evaluate an investment's opportunity by understanding the relationship between value and price. Two methods are key to this investment strategy. |
The Motley Fool
October 31, 2006
Emil Lee |
How to Calculate the Kelly Formula Although any formula is only as good as the estimates and data plugged into it, this formula forces investors to think in terms of payoffs and probabilities when investing in a company. |
